$3.25 billions for the 50% stake and on the top of that 12 % royalty first year and then 18 % Royalty upto $2B and 42% above $2b sale for the medicine that has been treating and killing of patients at the same time. They would not have any liability any more. What else do you want. I think it is the best deal.
Mr.Gizmondo: you are write, I was wrong. When I realized the mistake, it was too late. Any way 25% royalty is not bad.These people are working on parkinson and alzheimer, if they succede, ELN would be the stock of the century
Hopefully, they can reduce their staff and basic overhead. I wonder whom they're going to buy. Perhaps they'll change into a biotech financing company and invest in venture debt. That wouldn't be so bad. If the companies they invest in go bankrupt, they'll be first in line to pick the carcasses. They'l have to hire some smart biotech finance guys to accomplish this.